Maisons-Alfort and Marseille, France, October 6, 2014 - CleveXel Pharma, a highly experienced pharmaceutical developer that conforms fully with global regulatory compliance, today announces that it has been granted a license by the SATT Sud Est, a technology transfer accelerator in South Eastern France (Societe d’Acceleration du Transfert de Technologies Sud Est), to exploit two patents.
The license arose from SATT Sud Est development efforts and EUR 260,000 (USD 334,000) of funding. Under the terms of the agreement, CleveXel Pharma will pay a percentage of all revenue to SATT Sud Est. This will vary depending on the stage of development reached.
The first patent relates to the use of triazole nucleoside derivatives (TND) in the treatment of cancer, particularly azacitidine-resistant myelodysplastic syndromes (MDS) that may also develop into acute myeloid leukemia (AML). The second patent concerns a companion diagnostic test to identify the patients who are resistant to the standard treatment; azacitidine.
This project is the result of collaboration between three teams. The first one is led by Dr Patrick Auberger, director of the C3M (Mediterranean Center for Molecular Medicine, a reference center for oncology research founded by the French National Institute of Health and Medical Research and the University of Nice Sophia Antipolis). The second team is headed by Dr Rachid Benhida, deputy director of the Institut de Chimie (institute of chemistry) in Nice (ICN). Dr Thomas Cluzeau, a hematology resident at Nice university teaching hospital has also been involved. The project combines the support from SATT Sud Est, CleveXel Pharma’s background in pharmaceutical development and three complementary areas of academic expertise (biology, chemistry, and clinical practice) to overcome the technological hurdles.
This is the 20th pharmaceutical contract granted by SATT Sud Est. Since it was established in 2012, SATT Sud Est has granted about 30 licenses.
“CleveXel is a new player in pharmaceutical development that looks to win-win partnerships to share the risks associated with the development of health care projects,” said Olivier Freneaux, chairman of SATT Sud Est. “We feel confident that this exploitation license granted to CleveXel Pharma is just the first of what will become a lasting partnership.”
“For CleveXel Pharma, this partnership with SATT Sud Est paves the way for real innovation in oncology. We are very pleased with this agreement, which provides an ideal opportunity to showcase this innovative project, as we fulfill unmet medical needs. CleveXel Pharma’s know-how and expertise in drug development add value to this venture, instigated by SATT Sud Est,” said Christian Bloy, chairman and CEO of CleveXel Pharma. “We will make this license a flagship project in our portfolio and take it through to clinical development. We also appreciated the involvement of the researchers in chemistry, biology and clinical practice.”
This project is also supported by MATWIN (Maturation and Accelerating Translation With INdustry), a French national sourcing and support program for oncology research projects (the only one of its kind in Europe). MATWIN has the backing of the Canceropole PACA, the cancer research cluster for France’s Provence-Alpes-Cote d’Azur region, allowing researchers to take ownership of the challenges of technology transfer with feedback from industry experts.
About myelodysplastic syndromes (MDS)
Myelodysplastic syndromes are diseases that affect the bone marrow and can develop into leukemia. They generally affect older people around the age of 70, primarily men. The incidence of the disease worldwide is 4 cases per 100,000. Beyond the age of 60, this incidence ranges from 20 to 50 cases per 100,000. The three-year survival rate for patients is 35 per cent. The overall risk that a myelodysplastic syndrome will develop into leukemia is around 30 per cent. There are few treatment options, with just three drugs on the market. Around 40 per cent of patients are resistant to the standard treatment and, ultimately, all patients will become resistant to it. In 2010, the worldwide market for MDS was USD 746 million. This figure is expected to reach USD 1.7 billion by 2017 (source: GlobalData).
About SATT Sud Est
SATT Sud Est, ‘Accelerator of Technology Transfer’, helps companies to boost their competitiveness through innovation stemming from the public research of South Eastern France. It is a key player in regional economic development associated with innovation.
Its core business involves bringing inventions developed by its shareholder research bodies to readiness on legal (intellectual property), economic (market) and technical (proof of concept) levels. SATT is focused on bridging the technology gap between these inventions and their industrial-scale production. SATT aims at transferring innovative technologies stemming from its shareholders to the economic fabric while granting operating licenses to companies. SATT Sud Est is a simplified joint-stock company (SATT PACA Corse SAS) with capital of EUR 1 million. Its shareholders include the Universities of Aix-Marseille, Nice Sophia Antipolis, Toulon, Avignon and the Vaucluse, Corsica, the Centrale Engineering School of Marseille, the French National Centre for Scientific Research (CNRS), the National Institute for Medical Research (Inserm) and the Caisse des Depots. The Assistance Publique–Hopitaux de Marseille and the Nice University Hospital Centre are two of the company’s founding partners though they cannot be shareholders. 40 permanent employees and a further 21 on fixed-term contracts worked for the company as of Sept. 30, 2014. Its headquarters are based in Marseille, with a branch in Sophia Antipolis, France.
For more information, click here or follow our twitter account at @SATTse_ Browse our technology portfolio and create your account
About CleveXel Pharma
CleveXel Pharma is an innovative player in the French biotechnology landscape. The team has more than 20 years experience in pharmaceutical development. CleveXel specialises in the fields of oncology, central nervous system and immune inflammation. The company has created a new business model to optimize operational investment; CleveXel acts as a hub that integrates networks to support pharmaceutical research.
Its strategic positioning aims to bridge the gap between academic institutions and biotechnology industry groups. CleveXel selects the most promising opportunities by identifying the owners of molecules that emerge from disruptive innovation. CleveXel establishes the potential of molecules by evaluating them in a technical audit. This helps to catalyse the molecules development and increase their value and attractiveness for the pharmaceutical market.
CleveXel Pharma is a new type of business angel. It organizes the necessary funding with partners to bring a therapeutic project up to the stage of the proof of concept. At this point, the project can be monetized in the pharmaceutical industry. CleveXel Pharma provides partners with operational, preclinical and financial support. This can be in exchange for equity, or for the gradual acquisition of a license.
To date, CleveXel Pharma is engaged in five partnerships. In just 18 months, CleveXel Pharma has already scanned more than 130 projects. Fifteen have been selected; seven are in technical evaluation and eight are currently in development.
Media and analyst contact
Andrew Lloyd & Associates
Sarah Morgan / Sandra Regnavaque
sarah@ala.com / sandra@ala.com
Tel: +44 1273 675100
US: + 1 617 202 4491
Help employers find you! Check out all the jobs and post your resume.
The license arose from SATT Sud Est development efforts and EUR 260,000 (USD 334,000) of funding. Under the terms of the agreement, CleveXel Pharma will pay a percentage of all revenue to SATT Sud Est. This will vary depending on the stage of development reached.
The first patent relates to the use of triazole nucleoside derivatives (TND) in the treatment of cancer, particularly azacitidine-resistant myelodysplastic syndromes (MDS) that may also develop into acute myeloid leukemia (AML). The second patent concerns a companion diagnostic test to identify the patients who are resistant to the standard treatment; azacitidine.
This project is the result of collaboration between three teams. The first one is led by Dr Patrick Auberger, director of the C3M (Mediterranean Center for Molecular Medicine, a reference center for oncology research founded by the French National Institute of Health and Medical Research and the University of Nice Sophia Antipolis). The second team is headed by Dr Rachid Benhida, deputy director of the Institut de Chimie (institute of chemistry) in Nice (ICN). Dr Thomas Cluzeau, a hematology resident at Nice university teaching hospital has also been involved. The project combines the support from SATT Sud Est, CleveXel Pharma’s background in pharmaceutical development and three complementary areas of academic expertise (biology, chemistry, and clinical practice) to overcome the technological hurdles.
This is the 20th pharmaceutical contract granted by SATT Sud Est. Since it was established in 2012, SATT Sud Est has granted about 30 licenses.
“CleveXel is a new player in pharmaceutical development that looks to win-win partnerships to share the risks associated with the development of health care projects,” said Olivier Freneaux, chairman of SATT Sud Est. “We feel confident that this exploitation license granted to CleveXel Pharma is just the first of what will become a lasting partnership.”
“For CleveXel Pharma, this partnership with SATT Sud Est paves the way for real innovation in oncology. We are very pleased with this agreement, which provides an ideal opportunity to showcase this innovative project, as we fulfill unmet medical needs. CleveXel Pharma’s know-how and expertise in drug development add value to this venture, instigated by SATT Sud Est,” said Christian Bloy, chairman and CEO of CleveXel Pharma. “We will make this license a flagship project in our portfolio and take it through to clinical development. We also appreciated the involvement of the researchers in chemistry, biology and clinical practice.”
This project is also supported by MATWIN (Maturation and Accelerating Translation With INdustry), a French national sourcing and support program for oncology research projects (the only one of its kind in Europe). MATWIN has the backing of the Canceropole PACA, the cancer research cluster for France’s Provence-Alpes-Cote d’Azur region, allowing researchers to take ownership of the challenges of technology transfer with feedback from industry experts.
About myelodysplastic syndromes (MDS)
Myelodysplastic syndromes are diseases that affect the bone marrow and can develop into leukemia. They generally affect older people around the age of 70, primarily men. The incidence of the disease worldwide is 4 cases per 100,000. Beyond the age of 60, this incidence ranges from 20 to 50 cases per 100,000. The three-year survival rate for patients is 35 per cent. The overall risk that a myelodysplastic syndrome will develop into leukemia is around 30 per cent. There are few treatment options, with just three drugs on the market. Around 40 per cent of patients are resistant to the standard treatment and, ultimately, all patients will become resistant to it. In 2010, the worldwide market for MDS was USD 746 million. This figure is expected to reach USD 1.7 billion by 2017 (source: GlobalData).
About SATT Sud Est
SATT Sud Est, ‘Accelerator of Technology Transfer’, helps companies to boost their competitiveness through innovation stemming from the public research of South Eastern France. It is a key player in regional economic development associated with innovation.
Its core business involves bringing inventions developed by its shareholder research bodies to readiness on legal (intellectual property), economic (market) and technical (proof of concept) levels. SATT is focused on bridging the technology gap between these inventions and their industrial-scale production. SATT aims at transferring innovative technologies stemming from its shareholders to the economic fabric while granting operating licenses to companies. SATT Sud Est is a simplified joint-stock company (SATT PACA Corse SAS) with capital of EUR 1 million. Its shareholders include the Universities of Aix-Marseille, Nice Sophia Antipolis, Toulon, Avignon and the Vaucluse, Corsica, the Centrale Engineering School of Marseille, the French National Centre for Scientific Research (CNRS), the National Institute for Medical Research (Inserm) and the Caisse des Depots. The Assistance Publique–Hopitaux de Marseille and the Nice University Hospital Centre are two of the company’s founding partners though they cannot be shareholders. 40 permanent employees and a further 21 on fixed-term contracts worked for the company as of Sept. 30, 2014. Its headquarters are based in Marseille, with a branch in Sophia Antipolis, France.
For more information, click here or follow our twitter account at @SATTse_ Browse our technology portfolio and create your account
About CleveXel Pharma
CleveXel Pharma is an innovative player in the French biotechnology landscape. The team has more than 20 years experience in pharmaceutical development. CleveXel specialises in the fields of oncology, central nervous system and immune inflammation. The company has created a new business model to optimize operational investment; CleveXel acts as a hub that integrates networks to support pharmaceutical research.
Its strategic positioning aims to bridge the gap between academic institutions and biotechnology industry groups. CleveXel selects the most promising opportunities by identifying the owners of molecules that emerge from disruptive innovation. CleveXel establishes the potential of molecules by evaluating them in a technical audit. This helps to catalyse the molecules development and increase their value and attractiveness for the pharmaceutical market.
CleveXel Pharma is a new type of business angel. It organizes the necessary funding with partners to bring a therapeutic project up to the stage of the proof of concept. At this point, the project can be monetized in the pharmaceutical industry. CleveXel Pharma provides partners with operational, preclinical and financial support. This can be in exchange for equity, or for the gradual acquisition of a license.
To date, CleveXel Pharma is engaged in five partnerships. In just 18 months, CleveXel Pharma has already scanned more than 130 projects. Fifteen have been selected; seven are in technical evaluation and eight are currently in development.
Media and analyst contact
Andrew Lloyd & Associates
Sarah Morgan / Sandra Regnavaque
sarah@ala.com / sandra@ala.com
Tel: +44 1273 675100
US: + 1 617 202 4491
Help employers find you! Check out all the jobs and post your resume.
